APOE and ovarian carcinoma: APOA1 was reported to be associated with resistance to aromatase inhibitors in treatment of breast cancer131 and with resistance to carboplatin and paclitaxel, which are key chemotherapy drugs for epithelial ovarian cancer.132 It was reported that expression of APOD could be used as a novel biomarker of tamoxifen resistance in postmenopausal node‐positive breast cancer patients.133 Knockdown of APOE by siRNA reduced resistance of Hep3B cells to cardiac steroids through mediation of the Na+/K+‐ATPase signalosome.134